Literature DB >> 1538783

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

T A Yednock1, C Cannon, L C Fritz, F Sanchez-Madrid, L Steinman, N Karin.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an inflammatory condition of the central nervous system with similarities to multiple sclerosis. In both diseases, circulating leukocytes penetrate the blood-brain barrier and damage myelin, resulting in impaired nerve conduction and paralysis. We sought to identify the adhesion receptors that mediate the attachment of circulating leukocytes to inflamed brain endothelium in EAE, because this interaction is the first step in leukocyte entry into the central nervous system. Using an in vitro adhesion assay on tissue sections, we found that lymphocytes and monocytes bound selectively to inflamed EAE brain vessels. Binding was inhibited by antibodies against the integrin molecule alpha 4 beta 1, but not by antibodies against numerous other adhesion receptors. When tested in vivo, anti-alpha 4 integrin effectively prevented the accumulation of leukocytes in the central nervous system and the development of EAE. Thus, therapies designed to interfere with alpha 4 beta 1 integrin may be useful in treating inflammatory diseases of the central nervous system, such as multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538783     DOI: 10.1038/356063a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  457 in total

1.  The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Authors:  B Bourrié; E Bribes; M Esclangon; L Garcia; J Marchand; C Thomas; J P Maffrand; P Casellas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Combinatorial approaches to inhibitors of VLA-4: piperazine-peptoid-bisarylureas.

Authors:  I Lewis; B Rohde; M Mengus; M Weetall; S Maida; R Hugo; P Lake
Journal:  Mol Divers       Date:  2000       Impact factor: 2.943

3.  Encephalitogenic lymphoblast recruitment to resting CNS microvasculature: a natural immunosurveillance mechanism?

Authors:  R Alon
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

4.  Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels.

Authors:  P Vajkoczy; M Laschinger; B Engelhardt
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 5.  Regulation of experimental autoimmune encephalomyelitis by chemokines and chemokine receptors.

Authors:  Adam Elhofy; Kevin J Kennedy; Brian T Fife; William J Karpus
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 6.  Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?

Authors:  Tim Raine
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

7.  1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization.

Authors:  Inna V Grishkan; Amanda N Fairchild; Peter A Calabresi; Anne R Gocke
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

8.  Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse.

Authors:  Marika Merinen; Heikki Irjala; Marko Salmi; Ilkka Jaakkola; Arno Hänninen; Sirpa Jalkanen
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

9.  An increase in tolerogenic dendritic cell and natural regulatory T cell numbers during experimental autoimmune encephalomyelitis in Rras-/- mice results in attenuated disease.

Authors:  Avijit Ray; Sreemanti Basu; Nichole M Miller; Andrew M Chan; Bonnie N Dittel
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

Review 10.  Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal.

Authors:  Lawrence Steinman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.